Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


46.500 GBp 0.250 0.54%

As of 11:35:25 ET on 04/01/2015.

Snapshot for Vernalis PLC (VER)

Open: 48.000 Day's Range: 46.250 - 48.750 Volume: 263,473
Previous Close: 46.250 52wk Range: 28.750 - 53.000 1-Yr Rtn: +30.07%

Stock Chart for VER

No chart data available.
  • VER:LN 46.500
  • 1D
  • 1M
  • 1Y
Interactive VER Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VER

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.0060
Est. EPS (GBP) (06/2015) -0.0260
Est. PEG Ratio -
Market Cap (M GBP) 205.68
Shares Outstanding (M) 442.32
30 Day Average Volume 177,245
Price/Book (mrq) 2.5652
Price/Sale (ttm) 17.3183
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VER

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for VER

Vernalis plc is a revenue generating development stage pharmaceutical company which has a broad pipeline of research and development programs. The Company is focused on developing products for the US prescription cough and cold market. The Company derives pipeline candidates both from collaborations with global pharmaceutical businesses and their own research activities.

Ian GarlandChief Executive OfficerDavid MackneyChief Financial Officer
Tom ParkerSenior VP:Commercial OperationsPascal BorderiesSenior VP:Medical Affairs
More Company Profile & Key Executives for VER

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil